Sun Bioceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-10-2024
- Paid Up Capital ₹ 0.10 M
as on 23-10-2024
- Company Age 15 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.85 Cr
as on 23-10-2024
- Revenue 47.53%
(FY 2023)
- Profit -61.21%
(FY 2023)
- Ebitda -2.85%
(FY 2023)
- Net Worth 13.15%
(FY 2023)
- Total Assets 18.44%
(FY 2023)
About Sun Bioceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.85 Cr.
Gagan Bansal, Satyam Bansal, Anju Aggarwal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100DL2009PTC192244
- Company No.
192244
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jul 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sun Bioceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyam Bansal  | Director | 07-Dec-2020 | Current |
| Gagan Bansal | Director | 11-Jul-2020 | Current |
| Anju Aggarwal | Director | Current | |
| Dhruv Aggarwal | Director | Current |
Financial Performance and Corporate Structure Insights of Sun Bioceuticals.
Sun Bioceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 47.53% increase. The company also saw a substantial fall in profitability, with a 61.21% decrease in profit. The company's net worth Soared by an impressive increase of 13.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sun Bioceuticals?
In 2023, Sun Bioceuticals had a promoter holding of 66.00% and a public holding of 34.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Ethico Pharma Private LimitedActive 14 years 11 months
Gagan Bansal and Satyam Bansal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 May 2024 | ₹2.00 Cr | Open |
Hdfc Bank Limited Creation Date: 19 Jul 2021 | ₹3.52 M | Open |
Others Creation Date: 21 Mar 2016 | ₹1.50 Cr | Open |
How Many Employees Work at Sun Bioceuticals?
Unlock and access historical data on people associated with Sun Bioceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sun Bioceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sun Bioceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
